Likang Life Sciences   Report issue

For profit Phase 1
Founded: Shanghai China (2010)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03674073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Beijing Likang Life Science and Tech Co., Ltd. | Likang Life Sciences Holdings Limited

Active Ingredients

Drugs in Phase 1 Trials (2)

autologous dendritic cells loaded with autologous tumor lysate (1 trial)

lk101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Liver Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2